Citalopram Related Published Studies
Well-designed clinical trials related to Citalopram
Escitalopram treatment for depressive disorder following acute coronary syndrome:
a 24-week double-blind, placebo-controlled trial. [2015]
Augmentation of citalopram with aspirin for treating major depressive disorder, a
double blind randomized placebo controlled clinical trial. [2014]
A double-blind, randomized, placebo-controlled clinical trial of
S-adenosyl-L-methionine (SAMe) versus escitalopram in major depressive disorder. [2014]
Citalopram and escitalopram in the treatment of major depressive disorder: a
pooled analysis of 3 clinical trials. [2014]
Effects of escitalopram on markers of bone turnover: a randomized clinical trial. [2014]
Impact of escitalopram on vagally mediated cardiovascular function in healthy
participants: implications for understanding differential age-related, treatment
emergent effects. [2014]
Escitalopram for treatment of night eating syndrome: a 12-week, randomized,
placebo-controlled trial. [2012]
Effect of escitalopram on hot flash interference: a randomized, controlled trial. [2012]
Citalopram for agitation in Alzheimer's disease: design and methods. [2012]
No evidence for an anti-inflammatory effect of escitalopram intervention in
healthy individuals with a family history of depression. [2012]
Effects of reboxetine and citalopram on appraisal of infant facial expressions
and attentional biases. [2012]
Design and subject characteristics in the federally-funded citalopram trial in
children with pervasive developmental disorders. [2012]
Comparison of eye movement desensitization and reprocessing with citalopram in treatment of obsessive-compulsive disorder. [2011.11]
A review of escitalopram and citalopram in child and adolescent depression. [2011.11]
Escitalopram for the treatment of major depressive disorder in youth. [2011.10]
Randomized comparison of selective serotonin reuptake inhibitor (escitalopram) monotherapy and antidepressant combination pharmacotherapy for major depressive disorder with melancholic features: a CO-MED report. [2011.10]
Effectiveness and safety of citalopram in hospitalized adolescents with major depression: a preliminary, 8-week, fixed-dose, open-label, prospective study. [2011.09]
The treatment of minor depression with St. John's Wort or citalopram: failure to show benefit over placebo. [2011.07]
Melancholic, atypical and anxious depression subtypes and outcome of treatment with escitalopram and nortriptyline. [2011.07]
Improved insomnia symptoms and sleep-related next-day functioning in patients with comorbid major depressive disorder and insomnia following concomitant zolpidem extended-release 12.5 mg and escitalopram treatment: a randomized controlled trial. [2011.07]
Duration of response after treatment of mild to moderate depression with Hypericum extract STW 3-VI, citalopram and placebo: a reanalysis of data from a controlled clinical trial. [2011.06.15]
Remission of major depressive disorder without adverse events: a comparison of escitalopram versus serotonin norepinephrine reuptake inhibitors. [2011.06]
Methylphenidate but not atomoxetine or citalopram modulates inhibitory control and response time variability. [2011.05.01]
Elevated cortisol in older adults with generalized anxiety disorder is reduced by treatment: a placebo-controlled evaluation of escitalopram. [2011.05]
A single high dose of escitalopram disrupts sensory gating and habituation, but not sensorimotor gating in healthy volunteers. [2011.04.30]
Influence of citalopram and environmental temperature on exercise-induced changes in BDNF. [2011.04.25]
Escitalopram versus risperidone for the treatment of behavioral and psychotic symptoms associated with Alzheimer's disease: a randomized double-blind pilot study. [2011.04.15]
Prophylactic treatment with escitalopram of pegylated interferon alfa-2a-induced depression in hepatitis C: a 12-week, randomized, double-blind, placebo-controlled trial. [2011.04]
Testing anxious depression as a predictor and moderator of symptom improvement in major depressive disorder during treatment with escitalopram. [2011.04]
Open-label treatment with desvenlafaxine in postmenopausal women with major depressive disorder not responding to acute treatment with desvenlafaxine or escitalopram. [2011.03.01]
Efficacy of escitalopram compared to citalopram: a meta-analysis. [2011.03]
Quantification of cerebral blood flow as biomarker of drug effect: arterial spin labeling phMRI after a single dose of oral citalopram. [2011.02]
Citalopram reduces endotoxin-induced fatigue. [2011.02]
Efficacy of escitalopram for hot flashes in healthy menopausal women: a randomized controlled trial. [2011.01.19]
Are old-old patients with major depression more likely to relapse than young-old patients during continuation treatment with escitalopram? [2011.01.14]
Treatment of depression in type 2 diabetes with Fluoxetine or Citalopram? [2011.01]
Escitalopram for the treatment of major depressive disorder in youth. [2011]
Differential pattern of response in mood symptoms and suicide risk measures in
severely ill depressed patients assigned to citalopram with placebo or citalopram
combined with lithium: role of lithium levels. [2011]
Citalopram plus low-dose pipamperone versus citalopram plus placebo in patients
with major depressive disorder: an 8-week, double-blind, randomized study on
magnitude and timing of clinical response. [2011]
A single high dose of escitalopram disrupts sensory gating and habituation, but
not sensorimotor gating in healthy volunteers. [2011]
Relation of serotonin transporter genetic variation to efficacy of escitalopram for generalized anxiety disorder in older adults. [2010.12]
Citalopram versus other antidepressants for late-life depression: a systematic review and meta-analysis. [2010.12]
Treating depression to remission in older adults: a controlled evaluation of combined escitalopram with interpersonal psychotherapy versus escitalopram with depression care management. [2010.11]
[Efficacy of escitalopram vs paroxetine on severe depression with associated anxiety: data from the "Boulenger" study]. [2010.10]
Efficacy of escitalopram compared to citalopram: a meta-analysis. [2010.09.29]
Escitalopram in the treatment of negative symptoms in patients with chronic schizophrenia: a randomized double-blind placebo-controlled trial. [2010.08.30]
Comparative bioavailability of two escitalopram formulations in healthy human volunteers. [2010.08]
Antiplatelet effects of antidepressant treatment: a randomized comparison between escitalopram and nortriptyline. [2010.08]
Phase III, placebo-controlled trial of three doses of citalopram for the treatment of hot flashes: NCCTG trial N05C9. [2010.07.10]
Augmentation with citalopram for suicidal ideation in middle-aged and older outpatients with schizophrenia and schizoaffective disorder who have subthreshold depressive symptoms: a randomized controlled trial. [2010.07]
Impact of escitalopram on nocturnal sleep, day-time sleepiness and performance compared to amitriptyline: a randomized, double-blind, placebo-controlled study in healthy male subjects. [2010.07]
Desvenlafaxine and escitalopram for the treatment of postmenopausal women with major depressive disorder. [2010.07]
Escitalopram attenuates posterior cingulate activity during self-evaluation in healthy volunteers. [2010.05.30]
Escitalopram 20 mg versus duloxetine 60 mg for the treatment of chronic low back pain. [2010.05]
Urinary flow and urinary symptoms in elderly males exposed to either escitalopram or duloxetine. [2010.05]
MRP1 polymorphisms associated with citalopram response in patients with major depression. [2010.04]
Aripiprazole as adjunct to a mood stabilizer and citalopram in bipolar depression: a randomized placebo-controlled pilot study. [2010.03]
Baseline anxiety effect on outcome of SSRI treatment in patients with severe depression: escitalopram vs paroxetine. [2010.03]
Acute citalopram administration may disrupt contextual information processing in healthy males. [2010.03]
Escitalopram and enhancement of cognitive recovery following stroke. [2010.02]
Improving depression and enhancing resilience in family dementia caregivers: a pilot randomized placebo-controlled trial of escitalopram. [2010.02]
Effects of escitalopram on stress-related relapses in women with multiple sclerosis: an open-label, randomized, controlled, one-year follow-up study. [2010.02]
Evaluation of the influence of sex and CYP2C19 and CYP2D6 polymorphisms in the disposition of citalopram. [2010.01.25]
Area-specific modulation of neural activation comparing escitalopram and citalopram revealed by pharmaco-fMRI: a randomized cross-over study. [2010.01.15]
Serotonin transporter triallelic genotype and response to citalopram and risperidone in dementia with behavioral symptoms. [2010.01]
Effect of age, weight, and CYP2C19 genotype on escitalopram exposure. [2010.01]
Citalopram provides little or no benefit in nondepressed patients with irritable bowel syndrome. [2010.01]
Phase III, placebo-controlled trial of three doses of citalopram for the
treatment of hot flashes: NCCTG trial N05C9. [2010]
Escitalopram in the treatment of negative symptoms in patients with chronic
schizophrenia: a randomized double-blind placebo-controlled trial. [2010]
Citalopram provides little or no benefit in nondepressed patients with irritable
bowel syndrome. [2010]
Differential effects of escitalopram on attention: a placebo-controlled, double-blind cross-over study. [2009.12]
Escitalopram is a weak inhibitor of the CYP2D6-catalyzed O-demethylation of (+)-tramadol but does not reduce the hypoalgesic effect in experimental pain. [2009.12]
Open-label study of high (30 mg) and moderate (20 mg) dose escitalopram for the treatment of obsessive-compulsive disorder. [2009.11]
Specific effects of escitalopram on neuroendocrine response. [2009.11]
Suicidal ideation during treatment of depression with escitalopram and nortriptyline in genome-based therapeutic drugs for depression (GENDEP): a clinical trial. [2009.10.15]
Effectiveness of a quantitative electroencephalographic biomarker for predicting differential response or remission with escitalopram and bupropion in major depressive disorder. [2009.09.30]
Impact of CYP2C19 phenotypes on escitalopram metabolism and an evaluation of pupillometry as a serotonergic biomarker. [2009.09]
Escitalopram and venlafaxine for the prophylaxis of migraine headache without mood disorders. [2009.09]
Rationale and design of the participant, investigator, observer, and data-analyst-blinded randomized AGENDA trial on associations between gene-polymorphisms, endophenotypes for depression and antidepressive intervention: the effect of escitalopram versus placebo on the combined dexamethasone-corticotrophine releasing hormone test and other potential endophenotypes in healthy first-degree relatives of persons with depression. [2009.08.11]
Citalopram for continuation therapy after repetitive transcranial magnetic stimulation in vascular depression. [2009.08]
Comparison of pharmacokinetic profiles of brand-name and generic formulations of citalopram and venlafaxine: a crossover study. [2009.07]
Quetiapine augments the effect of citalopram in non-refractory obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled study of 76 patients. [2009.07]
Escitalopram in the treatment of adolescent depression: a randomized placebo-controlled multisite trial. [2009.07]
Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: citalopram ineffective in children with autism. [2009.06]
Effect of a single dose of citalopram on amygdala response to emotional faces. [2009.06]
A double-blind, placebo-controlled treatment trial of citalopram for major depressive disorder in older patients with heart failure: the relevance of the placebo effect and psychological symptoms. [2009.05]
Rationale, design and methodology of a double-blind, randomized, placebo-controlled study of escitalopram in prevention of Depression in Acute Coronary Syndrome (DECARD). [2009.04.07]
Effects of escitalopram on anxiety and respiratory responses to carbon dioxide inhalation in subjects at high risk for panic disorder: a placebo-controlled, crossover study. [2009.04]
Citalopram augmentation for subsyndromal symptoms of depression in middle-aged and older outpatients with schizophrenia and schizoaffective disorder: a randomized controlled trial. [2009.04]
Superiority of escitalopram to paroxetine in the treatment of depression. [2009.04]
Differential efficacy of escitalopram and nortriptyline on dimensional measures of depression. [2009.03]
A randomized controlled clinical trial of citalopram versus fluoxetine in children and adolescents with obsessive-compulsive disorder (OCD). [2009.03]
The selective serotonin re-uptake inhibitor escitalopram modulates the panic response to cholecystokinin tetrapeptide in healthy men depending on 5-HTTLPR genotype. [2009.03]
Two-week treatment with the selective serotonin reuptake inhibitor citalopram reduces contextual anxiety but not cued fear in healthy volunteers: a fear-potentiated startle study. [2009.03]
A randomized controlled clinical trial of Citalopram versus Fluoxetine in children and adolescents with obsessive-compulsive disorder (OCD). [2009.02.03]
Citalopram intervention for hostility: results of a randomized clinical trial. [2009.02]
Escitalopram: an open-label study of bereavement-related depression and grief. [2009.02]
Escitalopram for older adults with generalized anxiety disorder: a randomized controlled trial. [2009.01.21]
Changes in BDNF serum levels in patients with major depression disorder (MDD) after 6 months treatment with sertraline, escitalopram, or venlafaxine. [2009.01]
Pharmacokinetics and bioequivalence study of escitalopram oxalate formulations after single-dose administration in healthy Chinese male volunteers. [2009]
Citalopram augmentation for subsyndromal symptoms of depression in middle-aged and older outpatients with schizophrenia and schizoaffective disorder: A randomized controlled trial. [2008.12.23]
|